BALLERUP, Denmark — October 1, 2026

LEO Pharma A/S presented new data on Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) at the 35th European Academy of Dermatology and Venereology (EADV) Congress, highlighting real-world outcomes and quality-of-life improvements in adults and adolescents with atopic dermatitis (AD). In the TRACE study, more than 70% of adults with multiple high-burden areas affected by AD reported reductions in involvement after 12 months of tralokinumab treatment. High-burden areas included the head and neck, hands and feet, and genitals.

TRACE Data Show Reduced High-Burden Area Involvement

The TRACE subgroup analysis evaluated 742 adults with AD affecting one, two or three high-burden areas at baseline. Among patients with all three areas affected, 79.2% of those assessed at 12 months reported fewer affected areas, while 25.0% no longer reported involvement in any of the three areas. Among patients with two affected areas, 71.0% reported a reduction, including 28.0% who no longer reported involvement in either area. Of those with one high-burden area affected, 43.3% no longer reported involvement at 12 months. Quality of life also improved, with 76.9% of patients with a baseline DLQI score of at least 4 achieving a reduction of four or more points.

ADHAND Demonstrates Improvements in Hand Function and Quality of Life

Phase 3b ADHAND analyses showed significantly greater improvements with tralokinumab monotherapy than placebo in adults with moderate-to-severe hand involvement. At Week 16, 76.6% of patients receiving tralokinumab achieved at least a four-point reduction in DLQI compared with 44.7% with placebo. In a post hoc analysis, 59.7% achieved at least a 1.3-point reduction in the Hand Eczema Impact Scale (HEIS), compared with 22.8% with placebo. Improvements were observed across HEIS domains, including sleep quality and the ability to grip or hold objects. Tralokinumab also produced higher EASI-75 and EASI-90 response rates at Week 16.

Advertisement

cGxPJobs Banner

Long-Term Adolescent Data Support Continued Disease Control

Long-term data from the ECZTRA 6 and ECZTEND studies showed sustained responses in adolescents aged 12–17 years. Among 88 adolescents treated for up to approximately three years, response rates remained stable through most of the extension period, with EASI-75 responses of 80–85% and Children’s Dermatology Life Quality Index scores of 6 or below in 65–75% of patients. EASI-90 and IGA 0/1 response rates were approximately 50–60%. Tralokinumab was generally well tolerated, with most adverse events being non-serious and mild or moderate, and no new safety concerns identified.

Source: LEO Pharma, press release